COHANCE · Healthcare
Cohance Lifesciences Ltd. reported revenue of ₹676 cr for October to December 2024, +207.3% on the year and +11.9% on the quarter. It is the highest quarterly revenue in the last 7 quarters on record.
Operating profit (EBITDA) was ₹237 cr, a margin of 35.1%, +506 bps on the year and +112 bps on the quarter. Over the last 7 quarters the margin has ranged from 25.6% to 48.0%, averaging 34.8%. Operating costs grew +185.1% against revenue growth of +207.3%, so more of each rupee of sales reached operating profit.
Net profit was ₹153 cr, +225.5% on the year and +10.9% on the quarter, with earnings per share of ₹6.01. Profit before other income, one-offs and tax grew faster, at +258.8%; other income, one-offs or tax held the headline back. The tax rate of 25% is in line with its recent average.
On earnings per share of ₹16.51 over the last four quarters, the stock at ₹464.55 trades at 28.1 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Core profit grew faster than reported profit: one-offs held the headline down.
Reported profit +225.5% on the year; profit before other income, exceptional items and tax +258.8%.
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹231 cr | ₹220 cr | ₹253 cr | ₹488 cr | ₹604 cr | ₹676 cr | ₹840 cr | ₹549 cr | ₹556 cr | ₹545 cr | ₹619 cr | ₹422 cr |
| YoY | — | — | — | +40% | +161% | +207% | +232% | +13% | −8% | −19% | −26% | −23% |
| EBITDA margin | 42.4% | 30.0% | 28.9% | 25.6% | 33.9% | 35.1% | 27.3% | 20.4% | 21.8% | 17.4% | 16.0% | 0.2% |
| Other income, % of PBT | 19% | 22% | 24% | 18% | 9% | 11% | −2% | 10% | 19% | 2% | −90% | — |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 25% | 29% | 25% | 27% | 21% | 25% | 27% | 26% | 21% | 29% | 58% | — |
| Net profit | ₹80.0 cr | ₹47.0 cr | ₹53.0 cr | ₹75.0 cr | ₹138 cr | ₹153 cr | ₹117 cr | ₹46.0 cr | ₹66.0 cr | ₹29.0 cr | ₹8.0 cr | −₹45.0 cr |
| YoY | — | — | — | −38% | +73% | +226% | +121% | −39% | −52% | −81% | −93% | −198% |
| Core profit YoY | — | — | — | −45% | +86% | +259% | +206% | −32% | −57% | −78% | −77% | −196% |
| EPS | ₹3.13 | ₹1.84 | ₹2.10 | ₹2.96 | ₹5.44 | ₹6.01 | ₹4.73 | ₹1.28 | ₹1.94 | ₹0.96 | ₹0.51 | −₹0.63 |
| Flags | · | · | · | 1 | 1 | ✓ | ✓ | 1 | 1 | 1 | 1 | 2 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Cohance Lifesciences Ltd. reported revenue of ₹676 cr (+207.3% on the year) and net profit of ₹153 cr (+225.5% on the year) for October to December 2024.
Profit before other income, exceptional items and tax moved +258.8% on the year, against +225.5% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.